Fig 3.

Isolate susceptibilities and targeted VIM therapies. Includes all infectious episodes treated per patient; only the first isolate per infection. For bacteremia cases, the source isolate also listed when applicable. All doses adjusted for renal impairment by our ASP pharmacists. Abbreviations: BAL, bronchoalveolar lavage; DDKT, deceased donor kidney transplant; EOT, end of therapy; ET, endotracheal; inh, inhaled; IU, international units; IV, intravenous; MIC, minimum inhibitory concentration; OM, osteomyelitis; PNA, pneumonia; PO, by mouth drugs; AMK, amikacin; GEN, gentamicin; TOB, tobramycin; MEM, meropenem; LVX, levofloxacin; FOF = fosfomycin. ^aTotal duration of ATM plus CZA, or FDC backbone; alternative agents used empirically or as adjunction therapy are listed with their total durations in parenthesis. ^bCefiderocol and imipenem–cilastatin–relebactam approved and first available at our institution. ^cLevofloxacin breakpoint changed for Pseudomonas. ^dCLSI breakpoints for polymyxin B changed for Pseudomonas beginning Jan 2020: <2, intermediate; >4, resistant; no susceptible breakpoint. ^eSecond hospitalization during the study period.